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Abstract
Cryptosporidium species are protozoan parasites that infect epithelium sur-
faces in gastrointestinal and respiratory tracts of humans and a range of animals 
worldwide. Cryptosporidiosis has been associated with considerable morbidity 
and, under certain circumstances, mortality. Humans can acquire it by consuming 
food and drink containing oocysts, which have been recognised as a major cause 
for diarrhoeal disease. The ubiquitousness of the infective oocyst, its resilience to 
environmental pressures, and the low dose of oocyst exposure needed for infection 
amplify to outbreaks of Cryptosporidium traced to drinking and recreational water. 
Unlike in developing countries where lack of sustained access to safe water creates 
tremendous burdens of Cryptosporidium diarrhoea, this scenario is aggravated due 
to limited diagnosis and therapeutics. However, over the past few decades, growing 
information on Cryptosporidium genomes have allowed novel insight into the host-
parasite relationship. Future field research on potential tools will focus on biology-
derived parasite products applicable to drugs and diagnosis. This chapter reviews 
available data on biology, transmission, life cycle, diagnosis, genome, and a few but 
important progresses in the field of cryptosporidiosis.
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1. Introduction
Cryptosporidium species are protozoan parasites that infect the epithelial cells 
of the gastrointestinal and respiratory tracts of humans and a wide range of ani-
mals, with a global distribution [1–3]. Cryptosporidium represents a major public 
health concern for waterborne disease and daycare outbreaks of diarrhoeal disease 
worldwide [2, 4–8]. Human cryptosporidiosis is usually a self-limiting infection in 
immunocompetent individuals. However, cases of severe diarrhoea and dissemina-
tion to extra-intestinal sites can occur in children, the elderly, and individuals with 
impairment of T-cell functions, mainly those with HIV infection [9–12]. In children, 
although diarrhoea is a key feature of malabsorption, it may not be apparent at pre-
sentation; when the infection becomes chronic, the only symptom may be limited 
growth. Consequently, chronic infections can culminate in poor growth [5, 13–16]. 
The epidemiology of infections is complex and involves transmission by a faecal-oral 
route, either by ingestion of contaminated water or food or by human-to-human 
or animal-to-human transmission [17, 18]. The oocyst, the environmental stage 
of Cryptosporidium, is incredibly hardy, easily spread through water, and resistant 
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to inactivation by chlorine; and without the use of filtration, it is challenging to 
remove it from drinking water [19–21]. Cryptosporidium prevalence is higher in areas 
lacking a sanitation infrastructure, mainly drinking water and sewage, which led the 
World Health Organization (WHO) to include it in the water sanitation and health 
programme [22]. The scarcity of sustained access to safe water creates tremendous 
burdens of Cryptosporidium diarrhoea in developing countries [23]. Treatment and 
diagnosis options are still not totally effective [2, 24–26]. No fully effective drug 
therapy or vaccine is available for Cryptosporidium, and the diagnosis of cryptospo-
ridiosis has been based on the demonstration of oocysts in faeces, which present 
low sensibility [25]. However, the ability to culture relevant Cryptosporidium isolates 
in vitro, the development of novel gene-editing tools (knockout genes, CRISPR/
Cas9, and RNAi) [26–30], and ‘omic’ research (genomics, transcriptomics, and pro-
teomics) represent essential paths towards significant advancements in the control 
of cryptosporidiosis [30–38]. In the future, those approaches will show a holistic 
view of the biology of Cryptosporidium. In this chapter, we present recent advances 
and remaining challenges regarding human cryptosporidiosis under a public health 
perspective.
2. Clinical perspective, diagnosis, and treatment
Despite Cryptosporidium species infecting the epithelial cells of the gastroin-
testinal and respiratory epithelium tracts, human cryptosporidiosis is a usually 
self-limiting infection in immunocompetent individuals with a low fatality rate 
[39–41]. In general, onset of the symptoms occurs 5–7 days following exposure and 
resolves in 2–3 weeks [42]. Clinical manifestations vary from subclinical infec-
tion to watery diarrhoea, sometimes profuse. Other common symptoms include 
abdominal cramps, fever, flatulence, nausea, vomiting, and low-grade fever 
[43–45]. Clinical presentation of cryptosporidiosis in individuals with impairment 
of T-cell functions, mainly those with HIV infection, varies according to the level of 
immunosuppression, from asymptomatic disease, to transient disease, to relapsing 
chronic diarrhoea or even cholera-like diarrhoea that is debilitating and potentially 
life-threatening [46]. Spreading of infection beyond the extra-intestinal site (in the 
biliary or respiratory tract) has been documented in children and immunocompro-
mised people, resulting in a potentially life-threatening disease [47, 48]. Sclerosing 
cholangitis and other biliary involvements are common in AIDS patients with cryp-
tosporidiosis. Both innate and adaptive immunity of the host have major impacts on 
the severity of cryptosporidiosis and its prognosis.
Cryptosporidium has been diagnosed using a variety of approaches, such as 
microscopy, immunofluorescent antibody (IFA), enzyme-linked immunosorbent 
assay (ELISA), and DNA-based detection methods [18]. However, identification of 
the parasite’s morphologic features through examination of stool smears is widely 
employed in diagnostic laboratories, particularly in resource-limited health systems. 
The oocysts are shed intermittently [49]; therefore, three faecal samples collected 
on alternate days are recommended. To maximise the recovery of oocysts, Sheather’s 
sucrose flotation, saturated salt flotation, and Allen and Ridley’s formol-ether 
method are the stool concentration techniques most frequently used prior to the use 
of the microscopy staining technique [50, 51]. Stain differential is required due to the 
small size of the specimen (ranging from 4 to 6 μm), similar in shape to yeasts and 
faecal debris [52]. Safranin-methylene blue, Kinyoun Ziehl-Neelsen, and dimethyl 
sulfoxide-carbol fuchsin are the most commonly used stain methods [11, 53–55]. 
However, in the absence of staining solution, phase contrast microscopy has proven 
to be highly specific for the detection of Cryptosporidium oocysts in human stool 
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samples [56]. In general, conventional microscopy lacks sensitivity, is time-consum-
ing, and requires a skilled and well-experienced microscopist [57–59].
Direct fluorescent antibody tests (DFAs), enzyme-immunoassays (EIAs), and 
rapid immunochromatographic assays (dipsticks) are commercially available 
[60–63]. The EIA kits have been evaluated with human stool specimens only, pre-
sumably from patients infected with C. hominis or C. parvum. The direct fluorescent 
antibody tests have been widely used for the detection of Cryptosporidium in faecal 
smears, water, and food [60, 62–66]. However, the antigenic variability of oocyst 
wall epitopes contributes to reducing specificity, and the sensibility of all immu-
nological-based methods is low. High specificity (99–100%) has been generally 
reported for EIA kits. Sensitivities, however, have been reported to range from 70 
to 100% [62–65]. Dipsticks and EIAs are available for individual and for all-in-one 
tests for Giardia, Cryptosporidium, and Entamoeba histolytica [66–69]. The tests are 
fast and easy to perform. However, EIA kits and rapid format assays present a poten-
tial problem with false positives, so results need to be interpreted and evaluated 
with caution [70]. To overcome these barriers, one of the most notable advances in 
public health in recent decades has been the development of tools based on molecu-
lar biology for the diagnosis of infectious diseases. These polymerase chain reaction 
(PCR) techniques have enabled specific sensitive detection of oocysts (a single 
oocyst) in clinical and environmental samples [71–77]. Examples of such techniques 
include conventional PCR, quantitative PCR real time, and high-resolution melt. 
A wide variety of PCR methods targeting different genes have been developed for 
the detection of Cryptosporidium at the species/genotype/subtype levels. However, 
no targeted tests have been patterned for the detection of Cryptosporidium in 
clinical laboratories. Recently, the simultaneous qualitative detection and iden-
tification of multiple viral, parasitic (including C. parvum and C. hominis), and 
bacterial nucleic acids in human stool specimens were approved by the Food and 
Drug Administration (FDA) [78]. In general, PCR tools solely amplify the DNA 
of C. parvum, C. hominis, C. meleagridis, and species/genotypes closely related to 
C. parvum [18]. For genotyping, nested PCR-RFLP was the most commonly used 
method in the past. Nowadays, DNA sequencing of 18S has been required to reliably 
detect all Cryptosporidium spp. The HSP70 and COWP targets fail to detect the DNA 
of C. felis, C. canis, and C. muris [79]. Subtyping tools are indispensable from the 
epidemiological point of view and are helpful in knowing the possible transmission 
routes of Cryptosporidium species and zoonotic potential of the parasite. Several 
subtyping tools have been developed to evaluate the diversity within C. parvum 
or C. hominis, including analysis of the microsatellite, GP-60 gene, HSP70 gene, 
47-kDa protein, small double-stranded (ds) RNA virus, serine repeat antigen, and 
T-rich gene fragment [73, 80–85]. The 18S ribosomal RNA (rRNA) gene and the 
hypervariable 60-kDa glycoprotein (gp60) gene have been widely used as targets to 
identify species and track transmission [18, 86, 87]. The 60-kDa glycoprotein (gp60, 
also known as gp40/gp15) gene presents a wide genetic heterogeneity in the number 
of trinucleotide repeats (TCA, TCG, or TCT). This gene encodes a precursor protein 
that is cleaved to produce mature cell surface glycoproteins (gp45/gp40 and gp15) 
implicated in the attachment to, and invasion of, enterocytes [18, 87]. Identification 
of subtypes using GP60 subtype families has revealed the subtype families (Ia-Ik) in 
C. hominis [87–91] and two zoonotic subtypes (IIa, IId), subtypes (IIb, IIc, IIe, IIf, 
IIi, IIj-IIt) in C. parvum [4, 87, 92–94], and subtype families (IIIa to IIIg) in C. melea-
gridis have been acknowledged [87, 95, 96]. Subtyping tools targeting the gp60 gene 
have been developed recently for several other human-pathogenic Cryptosporidium 
species [87]. Species and subtype identification are not necessary for clinical care 
and therapeutic options but are important for epidemiological surveillance and for 
drug investigations and clinical trials. Novel diagnostic tools and biomarkers for 
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cryptosporidiosis, which could also be used for therapeutic or vaccine trials, are 
necessary for accurate identification.
Current treatment options for cryptosporidiosis are limited. So far, there is no 
vaccine against Cryptosporidium [97], and nitazoxanide (NTZ) is the only drug 
approved by the FDA for treatment of cryptosporidiosis in children and immuno-
competent adults [98]. However, it is not effective without an appropriate immune 
status and, consequently, is ineffectual for the treatment of immune-compromised 
patients, particularly those with AIDS [25, 99]. NTZ is a nitrothiazole benzamide 
compound with a broad spectrum of activity against a wide range of parasites, 
bacteria, and viruses. In protozoa, NTZ inhibits the enzyme pyruvate ferredoxin 
oxidoreductase, which is essential to anaerobic energy metabolism [100]. Due to 
the prevalence of cryptosporidiosis, the development of novel therapeutic targets 
and vaccines against Cryptosporidium spp. is a public health priority. The ongoing 
need to develop new anti-cryptosporidial drugs has spurred the process of finding 
new uses for existing drugs. Repurposing drug provides an attractive alternative to 
drug development [101]. Two compounds, 3-hydroxy-3-methyl-glutaryl-coenzyme 
A (HMG-CoA) reductase inhibitor, pitavastatin and auranofin (approved for 
the treatment of rheumatoid arthritis), have been shown to be effective against 
Cryptosporidium in vitro [102]. Auranofin has been shown to be 10 times more 
potent than metronidazole against Entamoeba histolytica, the protozoan agent of 
human amoebiasis [103]. HMG-CoA and auranofin have particular promise in fast-
tracking for further in vivo testing in animals and humans.
3. Life cycle and classification
The parasite has a complex monoxenous life cycle with both asexual (merogony) 
and sexual (gametogony) stages. Ingestion of an infective oocyst (containing four 
sporozoites) by a susceptible host initiates the excystation process in the gastroin-
testinal tract. The sporulated oocyst ruptures, releasing sporozoites that invade the 
enterocytes, inducing the cell membrane to enclose the parasite in the parasitopho-
rous vacuole, which then differentiates into a trophozoite. Trophozoites undergo 
merogony and form either a further type I meront or a type II meront, which con-
tains four merozoites that are destined for gametogony. Merozoites can differentiate 
into sexually distinct stages called macro- and microgametocytes in a process called 
gametogony. New oocysts are formed in the epithelial cells from the fusion of a 
macro- and a microgametocyte to form a diploid zygote. The new fused cell evolves 
and sporulates in situ in a process called sporogony, becoming oocysts containing 
four sporozoites. Type II meronts attach to the epithelial cell and differentiate into 
either macrogamonts or microgamonts. The microgametes from the microgamont 
are released, and each can fertilised a macrogamont to form a diploid zygote. This 
cell undergoes a process like meiosis (sporogony) to produce an oocyst, either thin- 
or thick-walled, containing four sporozoites (sporulated oocysts). The thin-walled 
oocysts are involved in autoinfection, and thick-walled oocysts are released within 
the faeces to infect new hosts [104–107] (Figure 1).
Until relatively recently, Cryptosporidium was classified as a coccidian parasite. 
However, the taxonomic placement of Cryptosporidium was altered after revisions to 
higher-order classifications due to recent particularities observed in Cryptosporidium. 
The parasite can develop in a cell-free culture, while extracellular stages have been 
observed in both cell-free and cell cultures, in biofilms, and in vivo [108–111]. It pres-
ents the ability to grow and amplify without host cell attachment and encapsulation, 
as well as the insensitivity of all anticoccidial agents [26]. Moreover, the parasite lacks 
a micropyle, sporocyst, and polar granular [111–113]. Although initially considered 
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to be a coccidian, Cryptosporidium spp. share features of both the coccidia and grega-
rines, confirmed by morphological and molecular data. Major similarities between 
Cryptosporidium and gregarine parasites are as follows: (1) the ability to complete 
its life cycle in the absence of host cells, (2) extracellular gamont-like stages, (3) the 
process in which two mature trophozoites pair up before the formation of gametocyst 
(szygy), and (4) changing cell architecture to adapt to diverse environments (biofilms, 
coelom, intestines, soil, and water) [107, 108, 111, 114]. The most recent classification 
considers Cryptosporidium as a separate group within the Apicomplexa. Analyses of 
comparative genomics and of phylogenetic inference and the ability of Cryptosporidium 
to complete its life cycle extracellularly confirm its close relationship with gregarines 
and corroborate the transference of Cryptosporidium to the Gregarinomorphea class as 
a new subclass of Cryptogregaria [111, 115]. Early taxonomy at species level was based 
originally on morphology and host specificity. Nowadays, the description of species 
Figure 1. 
A schematic diagram of Cryptosporidium life cycle. After ingestion of contaminated water and/or food, the 
oocyst wall opens (excystation) triggered by temperature, stomach acid, and bile salts. Then, sporulated oocyst 
ruptures releasing (a) sporozoites that (b) invade the host cell (c) inducing the cell membrane to enclose the 
parasite in the parasitophorous vacuole, (d) which then differentiates into a trophozoite that undergoes an 
asexual reproduction, (e) forming a type I meront that contains 6–8 merozoites. These merozoites can reinfect 
the epithelial cell, where they undergo merogony and form type I meront or (f) type II meront. (g) Merozoites 
can differentiate into sexually distinct stages called (g) micro- and (h) macrogametocytes. (i) Zygote is formed 
after the fertilisation of macrogametocyte by the microgametocyte, (j) and this cell undergoes sporogony and 
produces a thin-walled oocyst. (k) These thin-walled oocysts are released within faeces to infect new hosts, as 
well as (l) involved in autoinfection process (adapted from Ref. [104]).
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takes molecular analyses, mainly DNA sequencing and PCR-related methods, into 
account for the detection and differentiation of Cryptosporidium spp.
4. Maintenance of Cryptosporidium in nature and transmission
Once excreted into the environment, oocysts can be dispersed from the faecal 
matrix into the terrestrial environment (Figure 2). When present on the soil 
surface, oocysts may be exposed to high temperatures and desiccation, causing 
their inactivation. Oocysts are sensitive to desiccation and UV-C irradiation [116]. 
Reports show that desiccation is lethal to oocysts with only 3 and 5% remain-
ing viable after being air-dried at room temperature for 2 and 4 h, respectively 
[117, 118]. However, when within the soil column, the oocysts were maintained, 
protected, and viable [119, 120]. Studies have indicated that oocysts at 4°C 
recovered from soil column may remain infectious for long periods [119, 121]. 
These findings suggest that the soil column is a sanctuary for Cryptosporidium, 
protecting it until rainfall events scatter them [120]. Oocysts were able to remain 
viable and infectious after being frozen at −10°C for up to 168 h, at −15°C for 
up to 24 h, and at −20°C for up to 8 h [122]. Moreover, Cryptosporidium oocysts 
can be carried in the environment due to interactions with biofilms (surface-
attached microbial communities). They readily attach to biofilms and persist and 
subsequently separate from it. High concentrations of oocysts in water biofilms 
that were maintained over several months maintained viable sporozoites [123]. 
Cryptosporidium oocysts in fresh water and marine water can survive at a range 
of temperatures. Fayer et al. reported that oocysts maintained at 20°C remain 
infectious for 12 weeks at salinities of 0 and 10 ppt, for 4 weeks at 20 ppt, and for 
2 weeks at 30 ppt [124]. Although salinity can have a pronounced effect on oocyst 
infectivity, they can survive long enough in marine waters to justify their pres-
ence in marine animals.
Cryptosporidium spp. have a huge impact on both human and veterinary 
health worldwide, aggravated by the limited diagnosis and current therapeutics. 
Cryptosporidium spp. have a worldwide distribution and the ability to infect a wide 
range of hosts, including humans, and a broad variety of vertebrate [1, 3]. Humans 
can acquire cryptosporidiosis through several transmission routes, such as direct 
contact with infected persons or animals and consumption of contaminated water 
(drinking or recreational) or food (Figure 3).
Figure 2. 
Cryptosporidium sp. oocysts in safranin-methylene blue staining method.
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The WHO has categorised Cryptosporidium as a reference pathogen for the 
assessment of drinking water quality [125]. Susceptibility to cryptosporidiosis 
depends on several factors, including environmental conditions, host immune 
status, age, geographic location, and contact with infected humans/animals [126]. 
Animals play an important role in the maintenance, amplification, and transmis-
sion of Cryptosporidium [127]. In fact, a large range of animals are reservoirs for 
some species, genotypes, and subtypes, which may infect humans [128–130]. The 
lack of adequate instruments to continuously monitor animal mobility makes it 
difficult to study the dynamics of transmission [131, 132]. Also, oocysts are ubiq-
uitous in the environment and easily spread via drinking water, recreational water, 
and food [3, 133, 134]. The ubiquitousness of the infective oocyst, its resilience 
to environmental pressures [135], and the low-dose oocyst exposure (ingestion 
of fewer than 10 oocysts can lead to infection) [136, 137] amplify to outbreaks 
of Cryptosporidium traced to drinking and recreational water. In 1993, the larg-
est Cryptosporidium waterborne outbreak was recorded in the United States in 
Milwaukee, where more than 400,000 people were infected by the drinking water 
supply [138]. The epidemiology of infection is complex and involves transmission 
by the faecal-oral route, either by indirect transmission through ingestion of con-
taminated water or food or by direct human-to-human or animal-to-human trans-
mission [3]. The genus Cryptosporidium has about 30 species formally described, 
as well as various genotypes and subtypes. Some species are relatively promiscuous 
in terms of host specificity, some of which also infected humans. Currently, a wide 
range of Cryptosporidium species and various genotypes have been recognised as 
responsible for human cryptosporidiosis (Table 1).
Human infections predominantly are caused by C. hominis, which are consid-
ered restricted to humans (anthroponotic transmission), and by C. parvum, some 
of which isolate genotypes and infect ruminants (zoonotic transmission) [18]. 
However, in recent years, C. meleagridis, C. cuniculus, and C. ubiquitum have also 
emerged as species relevant to public health, while the other species tend to be 
associated only with sporadic and rare cases of human infection. Approximately 155 
Figure 3. 
Transmission cycles of Cryptosporidium infections.
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species of mammals have been reported as non-human hosts of C. parvum, indicat-
ing that the parasite is adapting and developing in many hosts [176].
The human-to-human spread is particularly well described within families 
(often secondary cases after a primary outbreak infection) in childcare nurseries, 
nursing homes, and hospitals [42, 177, 178]. In addition, contact with produc-
tion animals, mainly cattle, that are the main hosts of C. parvum can potentially 
infect humans [40, 178, 179]. To date, studies in developing countries have shown 
a predominance of C. hominis in HIV-positive children and adults. These findings 
are also valid in the United States, Canada, Australia, and Japan. In Europe and 
New Zealand, several studies have shown a similar prevalence of C. parvum and 
C. hominis in immunocompetent and immunocompromised individuals. Thus, in 
most developing countries, the anthroponotic transmission of Cryptosporidium 
Cryptosporidium spp. Major host References
C. andersoni Cattle [139–144]
C. baileyi Chickens and turkeys [145]
C. bovis Cattle [146, 147]
C. canis Dogs [148–150]
C. cuniculus Rabbits [151–155]
C. fayeri Marsupials [141, 156]
C. felis Cats [93, 157, 158]
C. hominis* Humans [18]
C. meleagridis* Turkeys, chickens,
humans
[18, 93, 153, 159, 160]
C. muris Rodents [161–163]
C. parvum* ruminants, especially calves [18]
C. scrofarum Pigs [164]
C. suis Pigs [139, 160, 165–167]
C. tyzzeri Rodents, snake [168]
C. ubiquitum Sheep and cervids [152, 154, 157, 158, 169]
C. viatorum Humans [93, 170]
C. erinacei Hedgehogs and horses [171, 172]
C. wrairi Guinea pigs [173, 174]
















*The most prevalent species.
Table 1. 
Currently recognised species of Cryptosporidium spp. associated with human infections.
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plays an important role in human cryptosporidiosis [18, 180], while in Europe, New 
Zealand, and rural areas of the United States, there are both anthroponotic and 
zoonotic transmissions. In Middle Eastern countries, children are mainly infected 
with C. parvum, but the significance of this occurrence is not clear [181]. An 
exception is Cryptosporidium infections in HIV-positive patients in Ababa, Ethiopia, 
where C. parvum is highly endemic and where contact with calves is an important 
risk factor for cryptosporidiosis [174].
In developing countries, most C. parvum infections in HIV-positive children 
and adults are caused by subtype IIc, with IIa largely absent, indicating that anthro-
ponotic transmission of C. parvum is common in these areas. Conversely, families 
of subtype IIa are commonly diagnosed in humans in industrialised regions, where 
their occurrence is often associated with contact with calves. Another family of  
C. parvum subtypes commonly found in sheep and goats, IId, is dominant in 
humans in Middle Eastern countries and is occasionally found in humans in some 
European countries, such as Sweden, where it is commonly diagnosed in dairy 
calves. A systematic review of the anthroponotic transmission of Cryptosporidium 
concluded that subtype IIc predominates in low-income countries with poor sanita-
tion and in HIV-positive individuals, unlike in higher-income countries, where it 
is rarely evident. Lacking effective treatment or vaccine, intervention to improve 
basic sanitation in these regions is the best option. This prophylactic action certainly 
may reduce the anthropogenic and zoonotic transmission of cryptosporidiosis, 
reducing the damage to human health. It is important to emphasise the importance 
of personal hygiene practices to minimise cryptosporidiosis, in addition to other 
pathogens transmitted by water and food.
5. Genome of Cryptosporidium: new insight and future challenges
Recent years have seen impressive progress of next-generation sequencing 
technologies in genome assembly and annotation methodologies, mainly by 
advancements in the fields of molecular biology and technical engineering and by 
reducing cost. Cryptosporidium has been the subject of genome sequencing projects, 
which have provided valuable insights into the species, biology, and host-parasite 
relationships. The genomic data of multiple Cryptosporidium species are available 
and accessible in a Cryptosporidium-dedicated database, CryptoDB (http://cryp-
todb.org/cryptodb/) [182], and in the GenBank database (www.ncbi.nlm.nih.gov). 
Comparative analyses have shown that Cryptosporidium genomes are highly com-
pact, containing 8.50–9.50 megabase pairs (Mbp), a total gene count ranging from 
3769 to 7610, and coding sequence composition (75–77.6%). Moreover, in general, 
they share a comparable GC percentage (Table 2).
Overall, gene content and genomic organisation among intestinal occurrences 
of the species are well conserved, with Cryptosporidium gene clusters encoding 
putative secreted proteins. Comparison of the Cryptosporidium genomes has 
identified a core set of proteins commonly studied, as well as major differences in 
particular gene families, which could be involved in biological differences between 
species and genotypes [114, 183–185]. Gene encoding proteins that are associated 
with invasion processes, e.g. protein kinases and thrombospondin-related adhesive 
proteins (TRAPs), insulinase-like peptidases, MEDLE secretory proteins, and 
mucin glycoproteins, are observed in genome Cryptosporidium spp. [32]. However, 
some of them differ in copy number variations of genes. Comparative genomic 
analysis revealed that one of the primary features differentiating Cryptosporidium 
species is the sequence diversity present in major secreted protein families, MEDLE, 
and insulinase-like proteases [184]. This is consistent with transcriptomic studies 
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of C. parvum, which have demonstrated MEDLE proteins in different subcellular 
locations that may perform their functions in distinct stages of the invasion and 
development process [33]. Moreover, a reduction in the number of genes encoding 
secreted MEDLE and insulinase-like proteins was observed in C. ubiquitum and  
C. andersoni, whereas the mucin-type glycoproteins are highly divergent between 
the gastric C. andersoni and intestinal Cryptosporidium species [184]. Unlike 
most other apicomplexans, Cryptosporidium spp. have no apicoplast or mito-
chondrial genomes but have remnant ones, the so-called mitosomes. However, 
Cryptosporidium species disagree from each other mostly in mitosome metabolic 














9.10 30.1 3818 3817
C. hominis TU502 — PRJNA 
13200
8.74 30.9 3949 3885




9.10 30.1 3796 3745




9.15 30.1 3769 3718




9.06 30.1 3995 3959




9.10 30.2 7774 7610




9.09 28.5 3897 3876




8.97 31.0 3806 3753




8.79 30.9 — —




8.70 31.0 — —




8.97 30.8 3766 3766






9.51 31.9 — —




9.05 32.0 — —




8.50 24.2 — —




9.18 25.8 — —




9.25 28.5 — 3934




9.26 31.1 — —
*Draft genome.
Table 2. 
Genomic features of Cryptosporidium spp.
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and a conventional electron transport chain [114], whereas C. ubiquitum has 
further reductions in ubiquinone and polyisoprenoid biosynthesis and has lost 
both the conventional and alternative electron transport systems, unlike C. muris 
genome encoding core enzymes for the Krebs cycle and a functional ATP synthase. 
Thus, the mitosome of C. muris functions essentially as a peculiar mitochondrion 
[186]. However, the loss of biosynthetic pathways is a common feature observed in 
Cryptosporidium spp. genomes, e.g. the cytochrome-based respiratory chain and 
main de novo synthetic pathways for amino acids, nucleotides, fatty acids, and the 
Krebs cycle [32, 183]. Conversely, families of transporters to acquire nutrients from 
the host were expanded, including transporters for amino acids, sugars, and ATP-
binding cassettes (ABCs) that drive the transport of various metabolites, lipids/
sterols, and drugs [32]. Although these genomic sequences provide valuable data, 
the genome analyses have revealed contradictory data and inconsistencies between 
the annotated gene models and transcriptome evidence [31, 36]. Notoriously, those 
findings are related to sequencing platforms, which have been applied to having 
different strengths and weaknesses and the use of different strategies and stringen-
cies in gene prediction.
Notwithstanding its novelty, the major challenges for the generation of 
whole genomes of Cryptosporidium are the quality and the yielding of limited 
DNA. Indeed, this is a critical step, as it is hard to recover enough quantity of DNA 
(2.5 × 10−5 highly purified oocysts correspondent approximately 10 μg) from faeces 
from natural infections. A theoretical estimate of the DNA content of one oocyst 
is of 40 fg [187]; therefore, it is tricky and arduous to recover enough quantity of 
DNA (2.5 × 10−5 highly purified oocysts correspondent approximately 10 μg) from 
unculturable samples with the quality necessary for high-throughput sequencing. 
Non-cultured samples may introduce a level of uncertainty and possess limited 
metadata. The lower the quality of the initial genome sequence, the higher the 
likelihood of yielding a missing or misassembled genome. A recent study evalu-
ated an alternative method of preparing faecal samples using the combination 
of salt flotation, immunomagnetic separation (IMS), and surface sterilisation of 
oocysts prior to DNA extraction. The method has shown promise when used for 
the genome sequencing of samples of C. parvum and C. hominis [36]. This chal-
lenging issue can be resolved using a novel approach of Cryptosporidium cell-free 
culture and new long-read sequencing techniques, which will likely be beneficial 
for improving data. Increases in the quality of the target DNA boost the depth of 
coverage of the genome in higher levels, so base calls can be made with a higher 
degree of confidence. Also, the ability to culture relevant Cryptosporidium isolates 
in vitro, the development of novel gene-editing tools (knockout genes, CRISPR/
Cas9, and RNAi), and ‘omic’ research (genomics, transcriptomics, and proteomics) 
represent essential paths towards significant advancements in the control of 
cryptosporidiosis.
6. Conclusions and future perspectives
Cryptosporidium is a major cause of diarrhoeal disease in humans worldwide, 
yet an effective therapy to eradicate the parasite is not available. Also, the diagnosis 
options remain limited in developing countries, which harm the surveillance and 
understanding of the epidemiology in resource-poor settings. In developed coun-
tries, large waterborne outbreaks in drinking and recreational water continue to 
occur, emphasising the need for better regulation and for improvements of drink-
ing water treatment processes and control guidelines. However, in recent years, 
significant improvements have been achieved in understanding the key concepts 
Parasitology and Microbiology Research
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of the organism, mainly by increasing the use of molecular methods and genome 
sequences. Recent advancements in knowledge of Cryptosporidium provide the basis 
for the development of effective and practical strategies for the future prevention 
and control of cryptosporidiosis. The data from Cryptosporidium genome sequences 
have already improved our understanding of the metabolism and cellular processes. 
In fact, mining the genome and proteome data of Cryptosporidium will allow 
the development of new classes of compounds and molecular targets. However, 
it is worth underscoring the need for community-wide efforts to generate and 
integrate high-quality functional datasets that span the full spectrum of biology 
and life cycles in order to improve the predictive nature of models generated from 
large-scale system-based resources. Transcriptomes and proteomics from different 
growth stages are starting to be generated and promise to provide further insight 
into the biology of Cryptosporidium. Also, future studies will require careful valida-
tion and follow-up of each finding using in vitro and animal model studies.
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